Does Glutathione-S-transferase associate with gastrointestinal cancer in Korean population?

December 16, 2009

The glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null genotypes have been linked to increased risk of developing cancer. The results regarding the association between GSTM1 and GSTT1 null genotypes and the risk of GC or CRC were contradictory. However, the majority of previous reports are limited by their small sample sizes. Therefore, the association of the GSTM1/GSTT1 null genotype with the risk of GC and CRC need to be confirmed in studies with larger numbers of samples.

A research article to be published on December 7, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Shin from Chonnam National University Medical School conducted a population-based, large-scale case-control study, to evaluate the association of GSTM1 and GSTT1 null genotypes with the risk of gastric and colorectal cancer in a South Korean population.

This is the first investigation of the risk of GC and CRC according to the GSTM1 and GSTT1 null genotypes in a large Korean population, and in addition, this study aims to determine whether smoking, alcohol consumption, and age modify the association between these polymorphisms and GC or CRC risk.

They found that GSTM1 and GSTT1 null genotypes were not associated with increased risk of GC or CRC in Koreans. Smoking, alcohol consumption and age did not modify the association. No difference in the frequency of the combined GSTM1 and GSTT1 null genotype was observed between the two cancer groups and controls.

Although there is a profusion of reports on the association of polymorphisms with GC or CRC risk, few of these results have been convincingly replicated. Therefore, large sample size replication studies are required to confirm these associations in the future.
-end-
Reference: Piao JM, Shin MH, Kweon SS, Kim HN, Choi JS, Bae WK, Shim HJ, Kim HR, Park YK, Choi YD, Kim SH. Glutathione-S-transferase (GSTM1, GSTT1) and the risk of gastrointestinal cancer in a Korean population. World J Gastroenterol 2009; 15(45): 5716-5721

http://www.wjgnet.com/1007-9327/15/5716.asp

Correspondence to: Dr. Min-Ho Shin, Department of Preventive Medicine, Chonnam National University Medical School, 5, Hak1dong, Donggu, Gwangju City, 501-746, South Korea. mhshinx@paran.com
Telephone: +82-62-2204166 Fax: +82-62-2330305

About World Journal of Gastroenterology

World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2008 IF: 2.081. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.

About The WJG Press

The WJG Press mainly publishes World Journal of Gastroenterology.

World Journal of Gastroenterology

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.